bh1, page-32

Hi Vin,

Additionally, that apparent high level lineage would also explain why SiYi appears so obscure and it would not surprise to find that there were other highly credentialled individuals involved in the JV with SiYi. I totally agree that if this is the case, the passage to market in China will be made a great deal easier. China is an enormous market for SBN and the value of its IP increases exponentially once a footprint is established and IP related sales are generated. Whilst there is no doubt that China is the primary company maker for SBN,any traction in Mexico will provide the company with near term commercial momentum that undoubtedly will make the current market valuation of $7.5m pale in comparison to its real, intrinsic (IP based) value.

I concede that it has to happen first, granted but drug testing is an emerging global market of considerable significance and SBN currently controls IP related best of breed technology products clearly capable of meeting the needs and demands of such an emerging market.

These are interesting times in more ways than one but sooner rather than later, SBN will be the subject of a sustainable market rerating that amongst other things, will provide acknowledgement of its future growth potential.

Thanks again for all the AGM summaries ( MH,BH1 and Stalagate),they have all been most helpful and appreciated.

cheers